Page last updated: 2024-12-07

isoguanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isoguanine is a naturally occurring purine base that is a structural isomer of guanine. It is found in various organisms, including bacteria, fungi, and plants. Isoguanine has been shown to have a variety of biological effects, including antiviral, anti-inflammatory, and anticancer properties. It is also known to be a potent inhibitor of the enzyme xanthine oxidase. Isoguanine has been studied extensively for its potential therapeutic applications, and research continues to explore its unique properties and potential benefits.'
```

isoguanine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

isoguanine : An oxopurine that is 3,7-dihydro-purin-2-one in which the hydrogen at position 6 is substituted by an amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID76900
CHEMBL ID506639
CHEBI ID62462
SCHEMBL ID432772
SCHEMBL ID134675
SCHEMBL ID4748766
MeSH IDM0051815

Synonyms (62)

Synonym
unii-e335pk4428
e335pk4428 ,
2h-purin-2-one, 6-amino-1,3-dihydro-
nsc 241501
einecs 222-157-6
3373-53-3
6-amino-3,9-dihydropurin-2-one
6-amino-3,9-dihydro-purin-2-one
isoguanine
nsc241501
2h-purin-2-one,3-dihydro-
nsc-241501
SR-01000637365-1
2-hydroxyadenine
6-amino-1,3-dihydro-2h-purin-2-one
I0370
CHEMBL506639
chebi:62462 ,
6-amino-1,7-dihydropurin-2-one
IGA ,
2-hydroxy-6-aminopurine
6-amino-2-hydroxypurine
2-oxoadenine
6-amino-3,7-dihydro-2h-purin-2-one
6-amino-9h-purin-2-ol
6-amino-7h-purin-2-ol
6-amino-3,9-dihydro-2h-purin-2-one
6-amino-3,7-dihydro-purin-2-one
A821910
AKOS006229677
AKOS016008986
CCG-47772
FT-0627419
FT-0611206
AKOS015854519
AKOS015896923
AKOS015904753
STL454962
SCHEMBL432772
SCHEMBL134675
fludarabine phosphate impurity, isoguanine [usp impurity]
2-oxyadenine
fludarabine phosphate impurity b [ep impurity]
2h-purin-2-one, 6-amino-3,7-dihydro-
guanopterin
SCHEMBL4748766
W-106766
6-amino-9h-purin-2-ol, aldrichcpr
DTXSID00187406
mfcd00142931
isoguanin
6-amino-3,7(9)-dihydro-purin-2-one
DS-5009
Q6085780
dihydro-2-oxoadenine
bdbm50497031
AMY38992
CS-0084463
HY-124143
C74731
EN300-2924752
SY057869

Research Excerpts

Overview

Isoguanine is an alternative nucleobase that has been proposed as a component of expanded genetic codes. It is an oxidation product of adenine in DNA that is mutagenic to the cell.

ExcerptReferenceRelevance
"Isoguanine is an alternative nucleobase that has been proposed as a component of expanded genetic codes. "( Photodynamics of alternative DNA base isoguanine.
de Vries, MS; Gate, G; Haggmark, MR; Sobolewski, AL; Šponer, J; Szabla, R, 2019
)
2.23
"Isoguanine is an oxidation product of adenine in DNA that is mutagenic to the cell."( Rescue of the orphan enzyme isoguanine deaminase.
Almo, SC; Dangott, LJ; Fedorov, AA; Fedorov, EV; Hitchcock, DS; Raushel, FM, 2011
)
1.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oxopurine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12Kd7.50007.50007.50007.5000AID1129829
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
folic acid-containing compound biosynthetic process2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
tetrahydrofolate biosynthetic process2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
folic acid biosynthetic process2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
magnesium ion binding2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase activity2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
ATP binding2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
kinase activity2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1129829Binding affinity to GST-tagged Escherichia coli HPPK expressed in Escherichia coli by SPR assay based alternative equilibrium affinity method in presence of AMP-CPP2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
The identification, analysis and structure-based development of novel inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase.
AID1129827Inhibition of GST-tagged Escherichia coli HPPK expressed in Escherichia coli using 6-hydroxymethyl-7,8-dihydropterin hydrochloride as substrate at 250 uM after 20 mins by luminescence assay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
The identification, analysis and structure-based development of novel inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase.
AID338748Inhibition of phosphatidylinositol 4-kinase in human A431 cell membrane by liquid scintillation counting
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (5.97)18.7374
1990's13 (19.40)18.2507
2000's32 (47.76)29.6817
2010's15 (22.39)24.3611
2020's3 (4.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.49 (24.57)
Research Supply Index4.29 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other66 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]